Portage Biotech Inc

NASDAQ:PRTGUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Portage Biotech Inc. is a clinical-stage immuno-oncology company. The Company is engaged in advancing therapies to improve long-term treatment response, and quality of life in patients with cancers. The Company’s access to technologies coupled with biological mechanisms enables the identification of clinical therapies and product development strategies, which accelerate these medicines through the translational pipeline. The Company’s portfolio consists of four platforms, with lead programs consisting of invariant natural killer T-cell (iNKT) engagers and a suite of treatments targeting the adenosine pathway. Within these four platforms, the Company has nine product candidates, of which five are pre-clinical and four of which are clinical stage. The Company’s portfolio also includes small molecule adenosine inhibitors, such as PORT-6, PORT-7, PORT-8 and PORT-9, which represent targeting the adenosine pathway.

Contact Information

Headquarters

Clarence Thomas Building, Road Town P.O. Box 4649TORTOLA, ON, Virgin Islands (British) VG1110

Phone

416-929-1806

Fax

416-929-6612

Executives

Chairman of the Board, Chief Executive Officer

Ian Walters

Chief Financial Officer, Secretary

Allan Shaw

Chief Scientific Officer

Robert Kramer

Vice President - Project Management and Operations

Steven Innaimo

Vice President - Development

Justin Fairchild